This story has been updated from a previous version to include comments from Bio-Rad's earnings call.

NEW YORK (GenomeWeb News) — Bio-Rad Laboratories reported after the close of the market today a 5 percent increase in fourth quarter revenues, driven by high-single-digit growth for its Life Science business.

The Hercules, Calif.-based company reported $602.6 million in revenues for the three months ended Dec. 31, 2013, up from $573.8 million a year ago, easily surpassing the average analyst estimate of $586.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.